Untitled
Previous | Next

Back to BW50
Home Page >>

The BusinessWeek 50 Ranking

26

Johnson & Johnson

In a year when its drug company rivals were stumbling, Johnson & Johnson continued to prosper. Its broad portfolio of businesses offset weakness in one market with strength in other lines. So while J&J's franchise in drug-coated cardiac stents and its blockbuster anemia drug Procrit lost steam to new competition, other prescription drugs and medical devices helped fuel an 18% increase in net income. The New Brunswick (N.J.) company's deep pockets came in handy: In late 2004, J&J struck a $24 billion deal to acquire cardiac-device maker Guidant Corp.

Company Info

2004 Rank24
STOCK INFO JNJ
Market Value $194.7 BILLION
Total Return (1-yr.) 24.0%
(3-yr.) 13.5%
2004 sales $47.3 BILLION
Sales Growth(1-yr.) 13%
(3-yr.) 13.8%
Net income $8.5 BILLION
Net Income Growth (1-yr.) 18%
(3-yr.) 14.0%
Net Margin* 18.0%
Return on Equity* 27.0%
Industry DRUGS & BIOTECH
CORPORATE WEB SITE
More in S&P 500 Companies Scoreboard >
*Trailing 12 months
Company data as of 2/28/05 provided by Standard & Poor's Compustat

  Related BW Stories

J&J: Don't Stop Dealmaking Now


Rewiring the Body


Health Care's Mixed Signals


Why Boston Scientific Is Pumping Again


Investing to Fight Disease

Company Snapshot

Johnson & Johnson engages in the manufacture and sale of various products in the health care field primarily in the United States. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment manufactures and markets various products used in the baby and child care, skin care, oral and wound care, and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. These products are marketed principally to the general public, and sold to wholesalers and directly to independent and chain retail outlets worldwide. The Pharmaceutical segment provides various products in the antifungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic, and urology fields. These products are distributed both directly and through wholesalers and health care professionals for use by prescription by the general public. The Medical Devices and Diagnostics segment includes various products, such as wound care and women's health products, minimally invasive surgical products, circulatory disease management products, blood glucose monitoring products, professional diagnostic products, orthopaedic joint reconstruction and spinal products, and disposable contact lenses. These products are distributed through surgical supply and other dealers to physicians, nurses, therapists, hospitals, diagnostic laboratories, and clinics. The company also operates in Europe, Africa, Asia, and Pacific. Johnson & Johnson was founded in 1887 by Robert Wood Johnson and is headquartered in New Brunswick, New Jersey.

No. of Employees

109,900


Data provided by Capital IQ
William C. Weldon

William C. Weldon, 56

Titles

Chairman of the Board, Chief Executive Officer and Chairman of Executive Committee

CEO Bio >

Total Compensation*

$5.7 MILLION

Total Value of Options**

$24.4 MILLION

Compare CEO Compensation >

Degrees Held

NA

Board memberships

Johnson & Johnson, JP Morgan Chase & Co.

* Latest available fiscal year
** The sum of the net value of options exercised and held in the latest available fiscal year

Key Executives

William C. Weldon (Board), Christine A. Poon (Board), Robert J. Darretta (Board), JoAnn Heffernan Heisen (Board), Russell C. Deyo (Board), Nicholas J. Valeriani (Board), Kaye I. Foster-Cheek (Board), Michael J. Dormer (Board), Colleen A. Goggins (Board), Per A. Peterson (Board), Joseph C. Scodari (Board)

Board Members

William C. Weldon, Gerard N. Burrow, James G. Cullen, M. Judah Folkman, Ann Dibble Jordan, Arnold G. Langbo, Leo F. Mullin, Henry B. Schacht, Michael J. Dormer, David Satcher, Mary Sue Coleman, Steven S. Reinemund, Robert J. Darretta, Susan Lindquist


Data provided by Capital IQ
Learn More